Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc. (AMLX) Stock Overview
Explore Amylyx Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
658.3M
P/E Ratio
-2.97
EPS (TTM)
$-3.10
ROE
-1.06%
AMLX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Amylyx Pharmaceuticals, Inc. (AMLX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 72.11, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $1.38.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -2.97 and a market capitalization of 658.3M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Analyst Recommendations
Price Targets
Company Profile
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Joshua B. Cohen
123
43 Thorndike Street, Cambridge, MA
2022